Polyethylene glycol 400 (PEG 400) is a low-molecular-weight grade of polyethylene glycol with a low-level toxicity. It is very hydrophilic, which renders it a useful ingredient in drug formulations to augment the solubility and bioavailability of weakly water-soluble drugs.

The global Pharmaceutical Grade PEG 400 market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime, Inc. (LPI) ' newest research report, the “Pharmaceutical Grade PEG 400 Industry Forecast” looks at past sales and reviews total world Pharmaceutical Grade PEG 400 sales in 2023, providing a comprehensive analysis by region and market sector of projected Pharmaceutical Grade PEG 400 sales for 2024 through 2030.

This Insight Report provides a comprehensive analysis of the global Pharmaceutical Grade PEG 400 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

• Low Aldehydes Content PEG 400
• Standard PEG 400

• Pharmaceutical Solvents/Diluents
• Medical Device Coating
• Cryoprotectant
• Surfactant
• Others

• Americas
• APAC
• Europe
• Middle East & Africa

• BASF Pharma
• SABIC
• Kimyagaran
• Dow
• Croda
• Clariant
• Ineos
• Finar (Actylis)
• Sanyo Chemical
• Shandong Ruisheng Pharmaceutical Excipient
• Jiangxi Yipusheng Pharmaceutical
• Liaoning Shengde Huaxing Chemical
• Liaoning Aoke pharmaceutical
• Jiangsu Dynamic Chemical

1. What is the 10-year outlook for the global Pharmaceutical Grade PEG 400 market?
2. What factors are driving Pharmaceutical Grade PEG 400 market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Pharmaceutical Grade PEG 400 market opportunities vary by end market size?
5. How does Pharmaceutical Grade PEG 400 break out by Type, by Application?